Literature DB >> 8968560

Antagonism of the effects of (+)-PD 128907 on midbrain dopamine neurones in rat brain slices by a selective D2 receptor antagonist L-741,626.

B J Bowery1, Z Razzaque, F Emms, S Patel, S Freedman, L Bristow, J Kulagowski, G R Seabrook.   

Abstract

1. The ability of PD 128907 to activate dopamine receptors in the ventral tegmental area, substantia nigra pars compacta, and striatum was investigated by use of in vitro electrophysiological recording and fast cyclic voltammetry. The affinity of a novel D2 selective antagonist L-741,626 for receptors activated by this agonist was measured to determine if its effects were mediated by D2 or D3 receptors. 2. The active (+) enantiomer of PD 128907 bound with high affinity and selectivity to rat D3 dopamine receptors. The Ki values for (+)-PD 128907 were 620 nM at D2, 1 nM at D3 and 720 nM at D4 receptors. 3. (+)-PD 128907 inhibited cell firing in both the ventral tegmental area and substantia nigra pars compacta with EC50 values of 33 nM (pEC50 = 7.48 +/- 0.10, n = 10) and 38 nM (pEC50 = 7.42 +/- 0.15, n = 5), respectively. No effects of (+)-PD 128907 (100 nM) were observed on glutamate or GABA-mediated synaptic potentials elicited by focal bipolar stimulation. 4. L-741,626 antagonized these effects of (+)-PD 128907 in a concentration-dependent and surmountable manner with an affinity, determined from Schild analysis, of 20 nM (pKB = 7.71 +/- 0.14) in the ventral tegmental area and 11 nM (pKB = 7.95 +/- 0.18) in the substantia nigra pars compacta. 5. (+)-PD 128907 also inhibited dopamine release in the caudate-putamen with an EC50 of 66 nM (n = 5). The affinity of L-741,626 for these nerve terminal autoreceptors (pKB = 7.71 +/- 0.06; = 20 nM) was identical to that observed on midbrain dopamine neurones. 6. These data demonstrate that the D3 receptor ligand (+)-PD 128907 is a potent agonist on rat midbrain dopamine neurones. However, its lack of regional selectivity, and the high affinity of the selective D2 receptor antagonist L-741,626 for receptors activated by (+)-PD 128907, was more consistent with an action on D2 autoreceptors rather than upon a D3 dopamine receptor subtype.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8968560      PMCID: PMC1915834          DOI: 10.1111/j.1476-5381.1996.tb16063.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  35 in total

1.  Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities.

Authors:  D S Kreiss; D A Bergstrom; A M Gonzalez; K X Huang; D R Sibley; J R Walters
Journal:  Eur J Pharmacol       Date:  1995-04-24       Impact factor: 4.432

2.  Functional relevance of dopamine receptors.

Authors:  G R Seabrook; S Patel; P H Hutson; C I Ragan; L J Bristow
Journal:  Trends Pharmacol Sci       Date:  1995-12       Impact factor: 14.819

3.  Dopamine D2 and D3 receptors inhibit dopamine release.

Authors:  L Tang; R D Todd; K L O'Malley
Journal:  J Pharmacol Exp Ther       Date:  1994-08       Impact factor: 4.030

4.  Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors.

Authors:  C L Chio; M E Lajiness; R M Huff
Journal:  Mol Pharmacol       Date:  1994-01       Impact factor: 4.436

5.  Comparison between the pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral tegmental area.

Authors:  B Bowery; L A Rothwell; G R Seabrook
Journal:  Br J Pharmacol       Date:  1994-07       Impact factor: 8.739

6.  Lack of discrimination by agonists for D2 and D3 dopamine receptors.

Authors:  K D Burris; M A Pacheco; T M Filtz; M P Kung; H F Kung; P B Molinoff
Journal:  Neuropsychopharmacology       Date:  1995-07       Impact factor: 7.853

7.  Biphasic inhibition of stimulated endogenous dopamine release by 7-OH-DPAT in slices of rat nucleus accumbens.

Authors:  J Patel; S J Trout; P Palij; R Whelpton; Z L Kruk
Journal:  Br J Pharmacol       Date:  1995-06       Impact factor: 8.739

8.  Functional expression of human D3 dopamine receptors in differentiated neuroblastoma x glioma NG108-15 cells.

Authors:  G R Seabrook; J A Kemp; S B Freedman; S Patel; H A Sinclair; G McAllister
Journal:  Br J Pharmacol       Date:  1994-02       Impact factor: 8.739

9.  Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907.

Authors:  T A Pugsley; M D Davis; H C Akunne; R G MacKenzie; Y H Shih; G Damsma; H Wikstrom; S Z Whetzel; L M Georgic; L W Cooke
Journal:  J Pharmacol Exp Ther       Date:  1995-12       Impact factor: 4.030

10.  Dopamine D3-preferring ligands act at synthesis modulating autoreceptors.

Authors:  C W Aretha; A Sinha; M P Galloway
Journal:  J Pharmacol Exp Ther       Date:  1995-08       Impact factor: 4.030

View more
  20 in total

1.  Olfactory modulation by dopamine in the context of aversive learning.

Authors:  Andrew M Dacks; Jeffrey A Riffell; Joshua P Martin; Stephanie L Gage; Alan J Nighorn
Journal:  J Neurophysiol       Date:  2012-05-02       Impact factor: 2.714

2.  Evidence for enhancement of gap junctional coupling between rat island of Calleja granule cells in vitro by the activation of dopamine D3 receptors.

Authors:  J V Halliwell; A L Horne
Journal:  J Physiol       Date:  1998-01-01       Impact factor: 5.182

Review 3.  Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice.

Authors:  T E Koeltzow; M Xu; D C Cooper; X T Hu; S Tonegawa; M E Wolf; F J White
Journal:  J Neurosci       Date:  1998-03-15       Impact factor: 6.167

4.  Dopamine D4 receptor subtype activation reduces the rat cardiac parasympathetic discharge.

Authors:  José Ángel García-Pedraza; Asunción Morán; María Luisa Martín; Claudia Ollauri-Ibáñez; Alicia Rodríguez-Barbero; Carlos M Villalón; Mónica García-Domingo
Journal:  Pflugers Arch       Date:  2020-08-21       Impact factor: 3.657

5.  Nicotine modulation of adolescent dopamine receptor signaling and hypothalamic peptide response.

Authors:  Celina Y Mojica; Jasmin M Dao; Menglu Yuan; Sandra E Loughlin; Frances M Leslie
Journal:  Neuropharmacology       Date:  2013-10-22       Impact factor: 5.250

6.  The dopamine D2, but not D3 or D4, receptor subtype is essential for the disruption of prepulse inhibition produced by amphetamine in mice.

Authors:  R J Ralph; G B Varty; M A Kelly; Y M Wang; M G Caron; M Rubinstein; D K Grandy; M J Low; M A Geyer
Journal:  J Neurosci       Date:  1999-06-01       Impact factor: 6.167

7.  Predominant role of the dopamine D3 receptor subtype for mediating the quinpirole-induced inhibition of the vasopressor sympathetic outflow in pithed rats.

Authors:  Inna Ruiz-Salinas; Abimael González-Hernández; Guadalupe Manrique-Maldonado; Bruno A Marichal-Cancino; Alain H Altamirano-Espinoza; Carlos M Villalón
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-02-19       Impact factor: 3.000

8.  Salvinorin A regulates dopamine transporter function via a kappa opioid receptor and ERK1/2-dependent mechanism.

Authors:  Bronwyn Kivell; Zeljko Uzelac; Santhanalakshmi Sundaramurthy; Jeyaganesh Rajamanickam; Amy Ewald; Vladimir Chefer; Vanaja Jaligam; Elizabeth Bolan; Bridget Simonson; Balasubramaniam Annamalai; Padmanabhan Mannangatti; Thomas E Prisinzano; Ivone Gomes; Lakshmi A Devi; Lankupalle D Jayanthi; Harald H Sitte; Sammanda Ramamoorthy; Toni S Shippenberg
Journal:  Neuropharmacology       Date:  2014-08-10       Impact factor: 5.250

9.  Regulation of dopamine D₃ receptor in the striatal regions and substantia nigra in diffuse Lewy body disease.

Authors:  J Sun; N J Cairns; J S Perlmutter; R H Mach; J Xu
Journal:  Neuroscience       Date:  2013-06-01       Impact factor: 3.590

10.  The role of dopamine D2, but not D3 or D4, receptor subtypes, in quinpirole-induced inhibition of the cardioaccelerator sympathetic outflow in pithed rats.

Authors:  A H Altamirano-Espinoza; A González-Hernández; G Manrique-Maldonado; B A Marichal-Cancino; I Ruiz-Salinas; C M Villalón
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.